Article
In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens.
Antimicrobial agents and chemotherapy - 1 Aug 2002
Petersen Peter J, Bradford Patricia A, Weiss William J, Murphy Timothy M, Sum P E, Projan Steven J
Abstract excerpt
Tigecycline (GAR-936) and daptomycin are potent antibacterial compounds in advanced stages of clinical trials. These novel agents target multiply resistant pathogenic bacteria. Daptomycin is principally active against gram-positive bacteria, while tigecycline has broad-spectrum activity. When tested by the standard protocols of the National Committee for Clinical Laboratory Standards in Mueller-Hinton broth II,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.